Glinta Plus 25 mg+5 mg (Tablet)

Unit Price: ৳ 40.00 (2 x 10: ৳ 800.00)
Strip Price: ৳ 400.00

Medicine Details

Category Details
Generic Empagliflozin linagliptin
Company Renata limited
Also available as
Glinta plus 10 mg tablet

Indications

  • Adjunct to diet and exercise
  • Improves glycemic control
  • Type 2 diabetes mellitus

Pharmacology

  • Linagliptin inhibits DPP-4 enzyme
  • Increases concentrations of active incretin hormones
  • Stimulates release of insulin
  • Decreases levels of glucagon
  • Empagliflozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
  • Reduces renal reabsorption of filtered glucose
  • Increases urinary glucose excretion

Dosage & Administration

  • Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily
  • Increased dose: 25 mg Empagliflozin and 5 mg Linagliptin once daily
  • Assess renal function before initiating
  • Do not initiate if eGFR is below 45 mL/min/1.73 m²

Interaction

  • Coadministration with diuretics
  • Coadministration with Insulin or Insulin Secretagogues
  • Rifampin decreased Linagliptin exposure
  • SGLT2 inhibitors increase urinary glucose excretion
  • Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Contraindications

  • Severe renal impairment
  • End-stage renal disease
  • Hypersensitivity reaction to Linagliptin or Empagliflozin

Side Effects

  • Pancreatitis
  • Ketoacidosis
  • Volume Depletion
  • Urosepsis and Pyelonephritis
  • Hypoglycemia with Concomitant Use with Insulin
  • Necrotizing Fasciitis of the Perineum
  • Genital Mycotic Infections
  • Hypersensitivity Reactions
  • Severe and Disabling Arthralgia
  • Bullous Pemphigoid
  • Heart Failure

Pregnancy & Lactation

  • Not recommended during second and third trimesters
  • Limited available data in pregnant women
  • Risks to mother and fetus with poorly controlled diabetes

Precautions & Warnings

  • Precaution in disease conditions like Pancreatitis, Hypotension, Ketoacidosis, Acute kidney injury, Urosepsis and Pyelonephritis, Hypoglycemia, Genital Mycotic Infections, Hypersensitivity
  • Acute pancreatitis has been reported in patients treated with Linagliptin
  • Reports of ketoacidosis in patients receiving SGLT2 inhibitors
  • Empagliflozin can cause intravascular volume depletion
  • Increased risk for urinary tract infections
  • Hypoglycemia with insulin use and insulin secretagogues
  • Necrotizing infection of the perineum, Genital mycotic infections, Severe and disabling arthralgia
  • An association between DPP-4 inhibitor treatment and heart failure observed in cardiovascular outcomes trials

Overdose Effects

  • Contact Poison Control Center in case of overdose
  • Usual supportive measures recommended
  • Removal of Empagliflozin by hemodialysis has not been studied
  • Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely

Therapeutic Class

  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

  • Store below 30°C
  • Keep away from light and wet place
  • Keep out of reach of children

Related Brands